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Teaser 
Reduced patient acceptability of generic products, especially oral ones, can undermine adherence and 
clinical effectiveness and hence compromise their potential benefits. 
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Research highlights 
Lack of formal scrutiny of the acceptability of generics may reduce patient adherence. 
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Abstract 
Optimum use of generic products would require equivalence, not only in terms of quality, safety and 
efficacy in clinical studies, but also patient acceptability in order not to jeopardize treatment success 
due to non-adherence which would de facto limit the potential cost saving anticipated by their use.  
Although acceptability is a requirement for the authorisation of paediatric innovator products, our 
survey of EU regulatory authorities uncovered that few have a formal process for assessing patient 
acceptability of generic products during the registration processes.  The current International Council 
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use focus on unifying 
guidance for the development and scrutiny of generics should include acceptability alongside the 
other factors being considered for harmonization. 
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Introduction 
Once a medicine is no longer under patent protection and the period of market exclusivity has 
expired it is likely that a generic version will become available.  The lower acquisition cost of generic 
medicines is a strong incentive for prescribers, pharmacists and health care systems to use them in 
preference to the innovator product, all other factors being equal.  Indeed, in some jurisdictions there 
is financial pressure on prescribers and pharmacists to supply the cheapest licensed product available.  
In others, generic substitution, even when a product is prescribed by brand name, is encouraged or 
even mandated [1].  In England, for instance, 84% of all drugs in primary care are prescribed 
generically, potentially generating significant savings for the National Health Service (NHS) [2]. 
In France pharmacists must provide a generic product even if the prescription is written by 
proprietary brand name.  The prescriber can only object to this substitution in the following three 
circumstances.  Firstly, if the medicine has a "narrow therapeutic index" (NTI) such as levothyroxine, 
phenytoin or theophylline and the patient is already effectively stabilized with a particular brand.  
Secondly, for children less than 6 years of age, if there is no generic drug in an age-appropriate dosage 
form available.  And finally, the original medicine may be prescribed if it does not include an excipient, 
present in all available generic medicines, to which patients have a demonstrated contraindication [3].  
If these conditions are not met and the branded product is supplied, the reimbursement process can 
become quite complex for the patient [4]. 
If all generic products were equally as acceptable as the original product this would be less of an 
issue.  However, this is not always the case. 
The purpose of this paper is to explore more formally the level of scrutiny of the acceptability 
aspects of generic product development and to highlight the added value of generics if non inferiority 
is achieved in terms of acceptability as well as bioequivalence (BE).  We discuss the findings of a 
purposive literature review of the relative palatability of generic products and corresponding impacts 
on medication adherence.  We also present the findings of a survey of a number of regulatory 
authorities, to establish whether the relative acceptability of generic products is one of the factors 
that are considered as part of marketing authorisation.  The outcomes of the review and the 
implications for product development are discussed. 
Although this paper focusses largely on oral medication, as the most commonly used mode of 
administration, the topics addressed are applicable to all product types, though each has their own 
critical acceptability criteria and challenges. 
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Given the expertise of the authors and the critical part that acceptability plays in paediatric 
medicine use, this paper focuses mainly on this patient group.  However, the main points are also 
applicable to some extent to all medicine users and in particular to other vulnerable patient groups 
such as the elderly and those with particular formulation needs such as those who experience 
swallowing difficulties and those with cognitive issues [5,6].  We have included occasional references 
to these groups where they serve to illustrate a particular point.  Since the focus of the paper is mainly 
on oral paediatric medicines many of the examples given are for antibiotic formulations since they are 
a class of medicines frequently prescribed for children [7,8] and they often have challenging 
organoleptic characteristics.  These are illustrative of the issue as a whole. 
Potential advantages of Generic products 
Generic products may offer several advantages over their innovator counterparts, not least in 
relation to costs.  A product that is normally a tablet may be easier to swallow; while a capsule can 
improve ease of administration for patients who need to mix the medication with food or disperse in 
water and administer via an enteral tube.  As another example, a liquid dosage form of a product 
which is usually a tablet may aid dose measurement. 
The packaging is also unlikely to be exactly the same, potentially offering scope to provide a 
product which the patient would prefer to handle or which is easier to differentiate from other 
medicines. 
Finally, there may also be scope for improving continuity of supply if generic products are available 
from several different manufacturers.  However, the counter to this is that if there are several generics 
available, different products may be supplied on different occasions with implications that are 
discussed below. 
Where such benefits arise, the mechanism and logistics of specifying a particular generic for supply 
to the patient and issues around reimbursement are likely to be problematic for the patient, prescriber 
and dispensing pharmacist.  For example, there is currently no formal mechanism for allowing a doctor 
to prescribe a particular generic or for the pharmacist to supply one from a particular supplier and to 
obtain reimbursement above and beyond the reference price should that particular generic be more 
expensive.  Even where the pharmacist does choose the generic product that will be stocked in their 
pharmacy it is unlikely to be economically viable to stock multiple versions. 
Although a specific generic could have enhanced acceptability to a particular patient relative to the 
innovator product, experience and literature reports suggest that the opposite is more likely the case 
[9,10].  A lack of consideration of the acceptability of generic products could undermine the potential 
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considerable cost saving and other advantages that could be achieved by promoting their use.  As with 
all medicines, it may be possible (but by no means certain) that acceptability could be improved by 
patient/provider education.  However, this is highly unlikely to be particularly effective for young 
children, the main focus of this paper, or for elderly patients with cognitive or functional impairments. 
Bioequivalence Considerations 
Generic products must be bioequivalent with the innovator or receive a waiver, for example, based 
on the Biopharmaceutical Classification System (BCS) class of the Active Pharmaceutical Ingredient 
(API) or meeting specified requirements for certain dosage forms or products [11-13].  To be 
bioequivalent, a suitable pharmacokinetic (PK) study (such as a randomised crossover or parallel 
design) in healthy volunteers needs to show, for both peak drug concentration (Cmax) and area under 
the curve, that the 90% confidence interval of the ratios (generic : reference) lie between 0.80 and 
1.25 [11].  To meet this requirement the variation in PK parameters between the generic and the 
reference is actually small [14], but nonetheless may have important implications, especially for 
medicines with a low therapeutic index (TI).  In these cases, the BE requirements are tighter (0.90 to 
1.11) and Cmax control may also be required.  However, differences in acceptability between both 
products could have a detrimental effect on adherence, as very simply, “drugs don’t work in patients 
who don’t take them” [15]. 
It is important in this context to remember that BE studies are generally performed in adults in 
controlled environments even for paediatric formulations when it will be children that actually take 
(or do not take) them in a domestic setting. 
Acceptability Considerations 
Currently, legislation and regulation-related guidance from the United States (US) Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) mandate development of 
formulations for children concurrently to those for new “innovator” products for adults.  Among other 
criteria, the acceptability of the formulation itself needs to be demonstrated [16].  As per EMA 
definition, acceptability is an overall ability of the patient and caregiver (defined as “user”) to use a 
medicinal product as intended (or authorised) [17]. 
Acceptability of a medicinal product is likely to have a significant impact on the patient’s adherence 
and consequently is likely to have an impact on the translation of a product’s into clinical effectiveness 
(that is, the performance of a medicine when used in the context of routine care) [18,19].  It is driven 
by the characteristics of the user (e.g. age, individual health status, behaviour, disabilities, background 
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and culture, prior expectations) and by the characteristics of a medicinal product.  For example, for 
oral dosage forms, these would be: 
• Palatability; (e.g. taste, flavour, sweetener, mouth feeling, product texture); 
• Swallowability (e.g. size, shape, “stickiness”, integrity of dosage form, film-coating); 
• Appearance (e.g. colour, size, shape, embossing); 
• Complexity of modification prior to administration (if required); 
• Required dose (e.g. the dosing volume, number of dose units, scoring); 
• Required dosing frequency and duration of treatment; 
• Selected administration device (if any); 
• Primary and secondary container closure system; 
• How the dosage form is to be taken and how often it is to be administered. 
Anecdotal evidence suggests that generic products (and in particular oral liquid dosage forms often 
used in paediatrics) may not/do not receive the same level of regulatory scrutiny as do innovator 
products in terms of their acceptability.  Although not always the case, this can lead to generic 
products being approved with poorer acceptability, which in turn can influence their clinical- and cost-
effectiveness via reduced adherence [20] as discussed. 
The lack of scrutiny of acceptability factors does not only affect paediatric medicines.  The situation 
is no better in the context of polypharmacy in older people, where patient-centric drug design should, 
but does not always, consider their needs, ability and preferences.  It is crucial to consider 
administration-related factors (e.g. difficulty in swallowing, handling and palatability) to ensure that 
efficacious treatments in clinical trials are effective in practice.  As an example size is an important 
acceptability driver for older patients [5].  Similarly taste masking should not be neglected for older 
patients even if it is often thought that older people are less sensitive to palatability issues [21]. 
Thus acceptability factors should be considered when assessing the suitability of particular 
formulations in meeting patients’ needs no matter what their age. 
A further aspect that should perhaps be considered when developing any medicine and, in the 
context of this paper, generic versions of innovator products, is their pharmaceutical elegance (those 
aspects of the product that the patient perceives as indicating its quality) and the expectations that 
this may produce within the patient.  There is a corpus of literature concerning the interaction 
between patients’ expectations produced by the packaging, the product, the environment and their 
prior experiences, on their subsequent perception of the acceptability of the final product and hence 
the likelihood that they will take it as intended.  Extensive discussion of this aspect is beyond the scope 
of this current paper but a few references are given to illustrate the concept [22,23]. 
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If there are multiple generic versions of a product available, then although some generics are 
formulated to match (as far as possible) the appearance and properties of the innovator product, this 
is not universally the case as they will be approved regardless, provided the product complies with all 
required standards of quality, safety and efficacy.  Even if the individual generic products are 
acceptable in their own right they can still differ significantly both from the innovator and each other 
including the possibility to differ in pharmaceutical form (e.g. tablet versus capsule, tablets of different 
size, shape and colour etc).  Given the supposed interchangeability of (generic) drugs, it is entirely 
possible for a different formulation to be supplied on different occasions (or between different 
pharmacies).  This can lead to frequent changes to the type, appearance, storage, dosing, 
administration requirements [24]; or organoleptic properties of medicines dispensed to the individual, 
which may lead to confusion and present a further barrier to adherence.  There is an additional risk of 
medication error, should the patient take more than one formulation of the same API at the same 
time with obvious therapeutic and toxicological sequalae. 
What actually happens in practice? 
To explore the issues concerning the acceptability of genetic medicines, we conducted a purposive 
literature review that focused mainly on paediatric populations; and conducted a survey of European 
regulatory authorities’ approaches to assessing the acceptability of generic medicines during their 
marketing authorisation review.  We also present our understanding of the regulatory situation 
outside Europe. 
a) Purposive review 
A search was performed in PubMed up until June 2019 using the search terms: (acceptability OR 
palatability OR taste) AND (drugs; generic OR drugs; non-proprietary) in order to identify publications 
that discuss the relative acceptability of innovator and generic versions of medicines. Therapeutic 
areas where acceptability issues are known to be a significant in paediatrics were also investigated 
namely anti-bacterial agents OR corticosteroid as exemplars of the issues discussed. These categories 
cover the most frequently prescribed oral medicines in children. Asthma treatments are not 
considered as these tend to be delivered via the pulmonary route. 
In addition, some publications highlighting the impact of formulation and presentation changes on 
the acceptability of an API were identified from a broad personal database—updated since 2014—
which gather papers on medicine acceptability in vulnerable populations. Herein we discuss 24 key 
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references that had a direct relevance to this paper.  Table 1 lists those key references and provides 
reasons for the few not discussed. 
Table 1 
Many studies have demonstrated differences in palatability between distinct formulations of an 
API.  As early as 1984, differences in children’s taste ratings were demonstrated among three different 
oral suspensions of bacampicillin as well as two penicillin syrups [25].  Two years later, Uhari et al [26] 
similarly highlighted acceptability differences for penicillin and erythromycin mixtures—varying in 
terms of sweeteners and flavours.  Indeed, an erythromycin mixture, flavoured with cherry/sodium-
citrate was significantly better than the mixture flavoured with pineapple/menthol, both on the basis 
of the time required to give the medicine to the child (as recorded by the nurse), and the subjective 
score of drug acceptance given by the nurses.  Such acceptability variation due to flavour were also 
observed for pivampicillin mixtures [27] and ondansetron syrups [28]. 
A study of US-approved antibiotic suspensions highlighted that the generics were rated lower or 
equal in taste to the respective innovator products [9,10].  The originator product tasted better than 
the generic product for trimethoprim-sulfamethoxazole, while there was no taste difference in 
relation to cephalexin and erythromycin-sulfisoxazole suspensions [10].  It is not clear in the latter 
case whether this was because all formulations were equally acceptable or equally unacceptable.  
Similar findings were observed for the acceptability of antibiotics approved in France [29,30].  While 
there was no significant difference between amoxicillin innovator and generic products, differences 
in palatability and acceptability between Augmentin and other co-amoxiclav products appeared 
significant [29,30].  These findings underlay a specific problem of oral generic antibiotic drugs, that is, 
of their acceptability to children and hence adherence to treatment courses [31-33].  Differences 
among reference and generic products have also been highlighted for other therapeutic contexts, such 
as corticosteroids which are frequently related to poor taste [34].  Although these results were based 
on human testing (e.g. child’s evaluation, observer reports), innovator and generic formulations could 
be also distinguished using biomimetic taste sensing systems [35].  These instrumental results were 
often correlated with those from gustatory sensation tests performed by well-trained adult volunteers 
[36-38]. 
In paediatrics, differences in acceptability between innovator and generic products appeared to be 
mainly due to taste and this in turn can be influenced by age.  Bagger-Sjoback and Bondesson showed 
in 1989 that taste differences could be driven by age of patient: two paediatric formulations of 
phenoxymethylpenicillin were differentiated by grade-schoolers (from 6 to 10 year) but less so by pre-
schoolers (from 3 to 5 years) [39]. 
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Other aspects identified in the search that had an influence on overall acceptability that differ 
between generics and innovator products in children include administration devices [40] and physical 
attributes such as size of solid dosage oral form [41]. 
Similarly, taste issues have often been overlooked in the elderly, another vulnerable population.  
Recent studies using a multivariable approach initially developed for paediatrics [42,43] then 
transposed for the older population [44], have highlighted that taste/palatability remains crucial for 
the acceptability and therefore correct use of oral liquid pharmaceutical products, especially in older 
women [6,21].  As for paediatric patients, studies of many aspects of a medicine’s characteristics are 
needed to better understand overall acceptability, from taste to administration device [40] or physical 
attributes such as size of solid dosage oral form [41]. 
Even for solid dosage forms where taste is less of an issue, the name, packaging, appearance, size, 
shape or pharmaceutical form (i.e. tablet or capsule) could cause confusion for some patients [45].  
Acceptability could also be affected by swallowability [45].  The potential for confusion, along with 
variability of presentations, were raised as the main disadvantages of generic products by general 
practitioners, who suggested that drug composition and packaging could be made uniform to mitigate 
some of the drawbacks associated with generics while taking advantage of their lower cost [46].  A 
recent cohort study supported this conclusion [47].  Based on more than 200,000 cases in the US, 
researchers highlighted that switching to a generic identical in composition and appearance to the 
innovator drug product was associated with lower switchback rates compared with switching to 
generic drug products that were different to the innovator [47].  Although low, there was still a degree 
of switchback from the “identical” generic to the innovator product. 
Although generic medicines have the same API as the innovator product and must be bioequivalent 
and of equal quality, they may differ in term of excipients and consequently in taste/palatability. 
For paediatric products, innovator products have to be tested to confirm acceptability during 
product development [17] since it is widely accepted that medicine acceptability could impact 
effectiveness.  In theory, an “identical generic” could be assumed to have identical acceptability to 
that of the innovator product.  However, producing a generic that is truly identical may prove to be a 
significant challenge.  For example, sourcing exactly the same flavours may be problematic and simply 
using similar ones may lead to significant organoleptic differences either initially or over the shelf life 
of the product as the flavour ages. 
If a generic is not identical in all respects to the innovator drug product, the same acceptability 
testing as that required for the innovator, should be considered by regulatory authorities.  As will be 
discussed in the next section, this may not always be the case. 
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Unacceptable medicines can impede the benefits of even the most effective drug, yet many 
parents and other carers are faced with the daily challenge of getting their children to take their 
treatments.  “I don’t like the taste” remains the number one challenge for children in taking medicines 
(over 60% of 652 respondents in a recent survey) [48]. 
b) Approach taken by European Regulatory Authorities 
To understand the current position of various regulatory authorities as regards to their 
requirements for acceptability testing of generic formulations, 31 national European Union (EU) 
regulatory agencies were emailed, either via personal contacts or via the EMA paediatric committee 
(PDCO) list, during the summer of 2019 [49].  The project was introduced, and the following questions 
were asked. 
• Does your country allow marketing approval of generics of different oral dosage forms to that 
of the innovator product? 
• Do some formal or informal discussions take place regarding acceptability of generic vs 
originator medicines? 
• What relevant regulatory documentation does your country use when considering this area? 
Responses were received from 14 (45%) regulatory agencies.  Belgium, Croatia, Denmark, Estonia, 
Greece, Iceland, Ireland, Latvia, Netherlands, Slovakia, Slovenia, Spain, Sweden, UK all answered that 
they allow marketing approval of generics of different oral dosage forms, if the conditions of Article 
10 of the Directive 2001/83/EC are fulfilled [50]. 
The responses varied from the very detailed to the very brief but were sufficient to provide a good 
level of understanding of the situation in Europe.  As presented in table 1, only three respondents 
(from UK, The Netherlands and Croatia) affirm that there was some level of formal scrutiny around 
acceptability of generic vs originator medicines at least for paediatric submissions.  Based on 
anecdotal data it is probable that informal discussion of these aspects may be more widespread, 
particularly in terms of tablet dimensions and shape.  However, it appears that discussion about the 
choice of flavouring is less common and formal requests for data on these aspects are rare. 
Table 2 
Surprisingly only 3 agencies report that they routinely formally consider acceptability when 
evaluating generic products given that differences between generic products and their originators 
products should be considered as part of the Risk Management Plan (RMP), as detailed in the EMA 
position paper on “Potential medication errors in the context of benefit risk balance and risk 
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minimisation measures” [51].  This concludes that “If a product containing the same active substance 
as an authorised/established one, but which is different in some aspects, including new indications, 
patient populations etc., is developed, the potential for medication errors caused by confusion with 
the authorised/established product, should be considered in the development and presentation of 
the product.”.  The guidance does not specifically reference acceptability, but perhaps it should do so. 
It appears that the risk of administration errors has been more formally recognised in the case of 
formulations for the elderly [52].  This reflection paper recognises that patients “commonly recognise 
oral preparations by their size, shape, colour, embossing, rather than by reading the product label, 
whereas preparations for other routes of administration may be recognized by their immediate 
container closure system”, and that even carers, whether in the home or in an institutional setting, 
“are also likely to administer medicinal products to the mainly older patients by a visual verification 
of the product appearance”.  It acknowledges that confusion based on these factors and changes in 
them can lead to medication errors.  Innovators are therefore encouraged to ensure that they 
“carefully compare the appearance and user instruction of their own product versus others on the 
market (e.g. sound or lookalikes)” and where relevant, to introduce “appropriate measures in the 
product characteristics such as the formulation, packaging or product information” to mitigate risk.  
Given the highlighted issues we encourage generic manufacturers to also ensure their products “have 
the same key visual appearance (i.e. colour, size etc.) and user instruction” as that of the originator 
product; the latter should be up to date and address older people’s specific needs.  As we point out 
elsewhere in the paper although this is highly desirable guidance it is not mandatory and not always 
applied in practice. 
Regulatory landscape outside Europe 
Our survey confirms that in the EU, competent drug regulatory authorities may allow a generic 
drug and its reference product to be different oral dosage forms if the product meets bioequivalence 
criteria.  In the US this is not the case.  The FDA does not allow a generic drug and its reference product 
to be different oral dosage forms (e.g. tablets and capsules).  In fact, the FDA guidance on “Size, Shape 
and other physical attributes of generic tablets and capsules” [41] recommends generic oral tablets 
and capsules to be of similar shape and size to the reference product (brand leader or originator 
product).  “Similar” can be interpreted as not identical allowing some increase in dimensions and 
weight.  However, this guidance does not mention testing of acceptability.  There is also an earlier FDA 
guidance on “Size of Beads in Drug Products Labeled for Sprinkle” [53].  This provides guidance on the 
maximum, but not minimum size of granules to be used in such “sprinkle” products to avoid them 
being chewed and applies to all such formulations.  However, there is no requirement for either the 
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formulation or the granule size to be the same for generics and the innovator product with clear 
potential for the organoleptic acceptability to differ.  This may be more important if such products are 
administered via a nasogastric tube. 
Our review is based on a Western developed world perspective.  Whilst many other territories 
follow either European or US regulatory standards and guidance, this is not always the case.  It was 
outside of the scope of this review to locate specific relevant guidance on the evaluation of the 
acceptability of generics in significant markets such as China, Africa, India and emerging markets.  
However, it seems likely that a lack of the scrutiny of acceptability of generics also applies in these 
markets.  Given issues of access and cost generic acceptability may be even more important in these 
territories than in Europe and the USA. 
Why does all this matter in clinical practice? 
Generic medicines are licensed in the EU in line with the requirements of Directive 2001/83/EC as 
amended [50].  Article 10 of the directive provides for 3 main categories of “generic” where a change 
of pharmaceutical form may result. 
• 10(1) a “true” generic medicinal product; 
• 10(3) a hybrid application; 
• 10(a) well established use (not actually a generic application, rather a formal recognition of 
medicines with a long and safe history of use). 
EU countries that allow marketing approval of generics base their assessment on bioequivalence 
of the generic to the innovator with acceptability playing a significantly lesser role at present.  
Although “a generic medicinal product” is defined as “a medicinal product which has the same 
qualitative and quantitative composition in active substances and the same pharmaceutical form as 
the reference medicinal product, and whose bioequivalence with the reference medicinal product has 
been demonstrated by appropriate bioavailability studies”, article 10.1 goes on to state that “the 
various immediate-release oral pharmaceutical forms include tablets, capsules, oral solutions and 
suspensions, are considered to be the same pharmaceutical form for the purposes of Article 10.”  This 
is also reflected in the Notice to Applicants (2A, chapter 1, section 5.3.2.1) and the Bioequivalence 
guideline [11]. 
As a consequence, there is no requirement for generic medicines to be the same colour, shape, 
size, etc. or to bear the same embossing as the reference product.  Nor does the pharmaceutical form 
need to be the same.  A generic tablet (article 10.1) referencing a capsule, or oral suspension, or oral 
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solution originator (or vice versa) would be acceptable and could obtain a marketing authorisation 
provided all other requirements are met. 
More changes are allowed in other article 10 applications.  Some recent examples serve to illustrate 
the point: 
• A 10.3 hybrid application for hydrocortisone granules in capsules for opening (Alkindi®) 
referring to hydrocortisone tablets [54].  The main differences in Alkindi® compared to the 
reference medicinal product are: change in pharmaceutical form; change in strength; 
indication in replacement therapy in paediatric patients only. 
• A 10.3 hybrid application for an orphan drug indication for mercaptopurine in treatment of 
lymphoblastic leukemia.  The generic oral suspension formulation references Puri-Nethol 
tablets [55]. 
• Sialanar® is an oral liquid dosage form containing glycopyrronium and is a 10a well established 
use (WEU) application.  Glycopyrronium has been licensed for many years.  Prior to Sialanar® 
oral liquid there were injections and solid dosage forms licensed.  The Sialanar® WEU 
application has resulted in new indications and a new dosage form for this drug substance [56]. 
The implications of this presumption of equivalence and hence presumed “substitutability” 
between various immediate release formulations is clearly not necessarily true in terms of 
acceptability. 
What are the product development implications? 
Based on the aforementioned published findings in the literature and information provided by the 
responses to the survey, it is possible to provide some detailed discussion for each of the individual 
factors that influence overall acceptability. 
Palatability 
At least some regulators are aware of the literature showing potentially significant differences 
between formulations, for instance one quoted the study referred to above which found that several 
brands of generic co-Amoxiclav tasted worse than the innovator (Augmentin) [29].  This study, which 
acknowledged financial support from the former French medicines agency (Afsaaps until 2012), called 
for the evaluation of palatability of future drugs (generics and references) before granting of the 
marketing authorization, since particularly for active substances of poor taste, palatability plays a 
significant role in adherence to the treatment, especially in children. 
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It is also acknowledged that other antibiotics also pose palatability challenges [33].  For example 
Floxapen®, the brand leader formulation of flucloxacillin has very poor palatability.  Anecdotally, many 
generic flucloxacillin brands are equally unpleasant.  This issue of poor palatability is highlighted in 
some hospital formularies.  For example, the formulary of Evelina Children’s Hospital, London, states: 
“Fucloxacillin liquid is not very palatable” [57].  The impact on adherence of unpalatable antibiotics is 
discussed on forums such as Mums Net and acknowledged internationally (e.g. pharmacists in Canada 
have suggested tips for giving antibiotics to children [58]). 
A recent example that is a good illustration of the need for generics to have acceptable palatability 
concerns two new licensed omeprazole products (two strengths).  Although the manufacturer 
intended this solution formulation to be used for administration via use with enteral tubes, as it is the 
only licensed formulation, it is being prescribed for oral use in the community.  However, the Neonatal 
and Paediatric Pharmacists Group (NPPG) blog reported recently [59] that “children don’t like it saying 
that it does not taste nice and ‘burns’.”  Some consider it “utterly revolting” and cases of emesis 
following swallowing of the dose have been reported.  Some children have asked to go back to their 
old (unlicensed) liquid formulation. 
In spite of the known issues of poor palatability of legacy, and some new, products some survey 
respondents were not aware of a major objection preventing the marketing of a product on the basis 
of poor palatability having ever been raised.  However, our survey reported one instance (personal 
communication) where a generic oral liquid product that was formulated at a higher concentration 
than the originator, presumably in order to reduce the dose volumes, and which the applicant 
originally proposed for use in both children and adults, was restricted to use in adults only as 
palatability was demonstrated to be worse than the more dilute reference product [60]. 
Poorly acceptable legacy products rely on voluntary reformulation by the marketing authorisation 
holder (MAH) as there is currently no regulatory instrument that would support a request for 
reformulation.  The paediatric-use marketing authorisation (PUMA) procedures have not incentivised 
alternative taste masked dosage forms. 
Modern regulatory procedures such as paediatric investigation plans (PIPs) along with such 
regulatory guidance as EMA guideline on paediatric development pharmaceutics, and their 
requirements for age appropriate, acceptable, formulations will prevent unpalatable innovator 
medicines for children in the future and force development of alternative formulations if taste cannot 
be masked.  For innovator products, acceptability/palatability studies will be performed as part of 
product development, probably as part of the clinical studies which companies will need to undertake 
in any case.  However, performing such studies in patients may not always be a requirement for 
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generic product developers.  If the API/product is BCS class I or III or an oral solution then they may 
not even need to undertake a bioequivalence study and thus will have no obligation (nor opportunity) 
to demonstrate the palatability of the product.  If they do undertake bioequivalence studies there is 
no requirement to include palatability assessment as part of those studies, and even if palatability 
studies are conducted the data will be generated in adults rather than children or the elderly.  
Including taste studies will of course increase the cost. Thus, the level of scrutiny applied to innovator 
and generic versions of those products is very different. 
Perhaps the subjectivity of taste and lack of defined methodology may contribute to regulatory 
uncertainty in this area.  A range of possible methodologies have been proposed and various groups 
including the European Paediatric Formulation Initiative (EuPFI), IQ Consortium and some regulators 
have begun discussions on identifying and agreeing unified methodologies for assessing the 
palatability and overall acceptability of pharmaceutical products but these efforts have yet to bear 
fruit. 
Swallowability 
Solid oral dosage forms (SODF) are being used increasingly for children.  The “Guideline on 
pharmaceutical development of medicines for paediatric use” [17] states that “The size and shape of 
a tablet are fundamental to the ability of a child to swallow it.  Therefore, the acceptability of the size 
and shape of tablets by the target age group(s) should be justified, and where relevant supported by 
appropriate studies or clinical evidence”.  Generic versions of a solid dosage form may be a different 
shape or size and so could be less acceptable especially if they are physically larger, or appear to be 
so.  This might be especially so if one product is a capsule whilst the other is a tablet and this will cause 
difficulties in generic substitution. 
As it is currently permissible at least in Europe for a generic to be a different pharmaceutical form 
to that of the innovator, swallowability might be improved by changing from a solid oral dosage form 
to a liquid.  However, taste issues may then be made worse and aspects such as portability and dose 
measurement may need to be considered.  It is not yet clear whether the risk of medication error is 
increased or reduced in such cases, and this will likely vary on a case by case basis. 
Appearance 
Enhanced acceptability has been suggested as one reason for inclusion of colours in medicines, 
especially for children.  The inclusion of colour either on packaging or in the dosage form itself may 
also be employed to help differentiate strengths. 
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Differences in colour may exist between innovator and generics products (and among different 
generics), in some cases, particularly over-the-counter (OTC) medicines, the same basic formulation 
may exist as either a coloured or colour-free presentation.  Although there is some evidence that 
adherence with prescribed therapy can be influenced by colour [61], there is a clear risk that 
differences in appearance (including form, size, shape, embossing and colour) could lead to elevated 
risks of medication errors.  These include selecting the wrong product at the pharmacy, patients taking 
the wrong tablets or wrong strength of tablet/wrong dose, taking multiple doses, etc.  This is 
potentially more problematic for patients on long term treatment who may receive several different 
generic products over time. 
Another aspect that deserves consideration in this regard is that different colourings may be used 
either to attempt to match the colour of another formulation or to provide an entirely different colour.  
Although reasonably rare some patients can be allergic to one or more of the dyes/lakes/colourants 
used to produce the coloured product [62-64].  The variation in excipients used can be beneficial if it 
allows a patient to avoid those colours to which they react but could clearly be an issue if a change of 
generic leads them to be exposed to a colour which they do not tolerate even if the appearance is the 
same.  Indeed, this may be a bigger risk if the appearance does not alert them to the fact that the 
colorants might have changed. 
Although medicines are provided in labelled packaging, for some patients their medicines may be 
placed in multi-compartment compliance aids (MCAs).  Changes in the appearance of medicines can 
be particularly confusing where they are separated from the packaging. 
Similarity of these aspects among all versions of the same product might help avoid these issues 
and facilitate safer generic substitution. 
Complexity of modification prior to administration 
As a generic product can be different to the originator in terms of the formulation and even the 
pharmaceutical form, the ease of dose preparation prior to dosing (such as reconstitution or 
dispersion in water/food to aid administration) may be very different.  As an example, a capsule may 
be easy to open for the content to be dispersed in water, whereas the tablet form might require 
crushing even if this is not allowed in the summary of product characteristics (SmPC).  Although there 
are occasional instances where it is legitimate practice to crush tablets for this purpose (e.g. clobazam, 
L-cysteine, liothyronine) it may be more convenient to patients and carers to open a capsule than to 
crush a tablet.  Similarly, a powder for reconstitution that requires more vigorous shaking could lead 
to a poorer patient experience or even dosing errors from undispersed material. 
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Sometimes it is necessary to dilute liquid preparations prior to administration via narrow enteral 
tubes e.g. to reduce viscosity.  As generic versions can vary with regard to excipients it is possible that 
ease of administration via enteral tubes may vary between products.  It is also possible that one might 
need dilution whilst another does not.  Increased complexity is clearly more likely to result in error as 
well as being less acceptable to carers.  The EMA has published guidance on instructions for enteral 
tube administration taking account the properties of the formulation [65]. 
Another example is where the innovator product or some generic versions are scored to aid dose 
adjustment but other versions are unscored or unlicensed for sub-division [66].  This may require 
unlicensed manipulations or the need for a specific makes of a medicine which can adversely affect 
generic substitution. 
Required dose 
It is possible that the costs of formulating and registering specific generic products for various 
paediatric patient groups are not commercially worthwhile.  Unlike the case for the innovator, there 
is no compulsion for generic products to cater for all users and so generic manufacturers may simply 
choose not to seek authorisation for use of their products in certain sub groups or may delete 
indications for use in younger children if issues regarding suitability for use in these groups are raised.  
Some regulators have termed this “age-upping” and are concerned as the direction of travel should 
be increased availability of licensed medicines for all age ranges, especially the youngest. 
As an example, given the relatively small market represented by neonates it is possible that generic 
manufacturers will not specifically develop formulations for all age groups but rather seek to adapt 
their adult or paediatric formulations for all age groups.  Very small volumes of oral liquid medicines 
are sometimes required for neonates.  Carers can struggle to measure such volumes.  Even though 
official guidance provides help on minimum volumes to be measured with devices there is still the 
possibility that a specifically formulated product for neonates will be a different concentration to one 
adapted from an adult or paediatric formulation for a wider age range leading to different dose 
volumes.  The smaller the dose volume, at least as a percentage of the overall volume of the dosing 
device (such as an oral syringe), the bigger the risk of dosing error—even if the dose is within 
“acceptable” limits.  If the therapeutic index is narrow this could be even more problematic. 
These differences in the age ranges of generic products compared to the innovator do not aid 
generic substitution.  It may also dilute the economic benefit of using generics since it may be 
necessary to use one formulation (innovator) in some patient populations whilst being able to use 
another (generic) one in others complicating inventory requirements and costs in the pharmacy or 
increasing unintentional off-label use of some medicines. 
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Device 
The “Guideline on pharmaceutical development of medicines for paediatric use” [17] states “unless 
otherwise justified liquid paediatric medicines should be supplied with a measuring device” and “the 
age appropriateness of an administration device should be discussed”.  There is also an EMA questions 
and answers (Q&A) document on gradations on oral liquid dosing devices [67].  However, there is no 
requirement for any administration device provided to be similar between formulations even of the 
same API.  Clearly if the ease of use of the device supplied can both influence acceptability and dose 
accuracy.  A proliferation of devices could lead to confusion and the wrong dose being administered. 
Some respondents to our survey stated that the supply of measuring devices with products that 
are inaccurate or inappropriate for the age range/dose volume is a common assessment issue with 
generic applications as illustrated by the need for advice to applicants on this [67].  If the application 
is subsequently approved, it will be necessary for the manufacturer to have responded to this 
guidance to ensure that the eventual device supplied is appropriate.  The costs involved may again 
mean that the manufacturer may choose not to pursue this indication. 
In some hospital environments the issue of different devices being supplied may be somewhat 
mitigated by them choosing not to use the devices that come in packs and using their own bulk ones 
to avoid staff errors in picking a device.  However, this has its own issues associated with dose 
measurement and dose accuracy as discussed in a recent seminar of the EuPFI on the topic [68]. 
Primary and secondary container closure system 
Generic medicines are not required to be packaged in the same way as the innovator.  Pack sizes, 
printing, colour, etc, may be different to the innovator.  If the pack is less convenient for the user, then 
acceptability may be affected, especially if it is less portable.  Conversely a generic manufacturer may 
be able to “spot a gap” in the market by providing packaging with enhanced functionality and thus 
provide their product with a competitive advantage.  Differences in external packaging can lead to 
errors in product selection.  The packaging design and style of generic medicines is usually not a copy 
of the original product (because of copyright and intellectual property rights) but is usually in 
accordance with the company-specific livery. Regulatory emphasis is on innovative pack design across 
manufacturers’ product ranges which should ensure accurate identification of the individual products 
and differentiate between products in a range [69]. 
Importantly, if there is a risk of several pack types of the same medicine (for example a tub of 
tablets and a blister pack) being in the patient’s home at the same time there could be a risk of both 
being taken leading to overdose.  Manufacturers should therefore consider this risk when making 
decisions about how to package their products. 
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Constraints on Generic manufacturers 
Whilst the forgoing discussion of various aspects of product development illustrates the potential 
risks of not considering acceptability as part of the approval of generic formulations (and hence the 
risk that this will not be high on the list of criteria being considered by the formulator), it has to be 
acknowledged that there are some constraints operating for the generic manufacturer, especially if 
the wish is to produce a product that is identical to the originator.  The appearance, dosage device, 
and packaging of an innovator product may be protected by intellectual property rights that may 
outlive the patent protection for the API.  There may also be risks associated with generics being 
passed off as the innovator product, although for reasons discussed earlier, it is unlikely for generic 
manufacturers to obtain exactly the same flavours, colours, excipient grades and so on.  Exact copies 
of the innovator should not be necessary and perhaps in many cases not even desirable if there is an 
opportunity for the generic to have better acceptability than the originator. 
There is also a cost involved in demonstrating that the generic product has acceptability that is at 
least not significantly worse than the originator, and this cost will need to be recouped by the 
developer.  A “level playing field” in this aspect of the evaluation of all generic products by regulatory 
authorities is therefore required to ensure that manufacturers are not disadvantaged economically 
for developing products which are demonstrably acceptable to the patient.  A slightly higher generic 
price for a product with good acceptability would avoid the economic risks associated with poorly 
acceptable generics, as discussed below. 
Economic considerations and implications 
The general assumption, and drive for generic prescribing in many countries is on the basis of 
saving costs for equal health gains [70].  From an economics perspective, the implicit approach when 
two products are therapeutically identical is one of cost-minimisation analysis, which has a decision 
rule of adopting the least costly option.  However, as described in the foregoing, bio-equivalence (in 
the pharmacokinetic sense) may not necessarily translate to therapeutic equivalence (in the clinical 
sense) if there are differences in the characteristics of generic medicines that might impact patient 
preferences, introduce barriers to administration or lead to medication errors.  These can each reduce 
adherence, limit effectiveness and cause harm.  Consequently, a cost-minimisation framework is not 
appropriate where such differences exist.  Likely differences in health outcomes, however small, 
dictate that cost-effectiveness (utility) analyses should be employed when assessing the value of 
generic products that are potentially not therapeutically equivalent [71]. 
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Generic medicines are generally exempt from formal health technology assessment and appraisal 
in most jurisdictions.  However, the Scottish Medicines Consortium (SMC) has a broad appraisal remit.  
In the case of hydrocortisone granules in capsules (Alkindi®), the SMC accepted that bioequivalence 
with hydrocortisone tablets had been established in clinical studies.  The premise of the sponsor’s 
economic analysis was for quality of life benefits and reduction in mortality from reduced risk of co-
morbidity resulting from the ability of Alkindi® to deliver accurate and consistent dosing in young 
children [72].  In Germany this argument was not accepted [73] and as a result the statutory health 
insurance funds agreed on a reimbursement that is not as high as the manufacturer proposed, but 
higher than for that for the comparator product (tablet formulation or compounded capsule 
formulation). 
The SMC accepted both mercaptopurine oral suspension (Xaluprine®) [74] and glycopyrronium 
bromide (Sialanar®) [75] for use by NHS Scotland without consideration of economic factors. 
More generally in the UK, the prescribing of generic medicines is typically driven by pressure from 
commissioners and providers of medicines in their various guises (general practices, Clinical 
Commissioning Groups, etc.) to reduce costs.  Formal economic evaluations are not conducted, and 
the consequences of this may lead to inefficiencies in the delivery of healthcare.  Consider, for 
instance, a generic medicine which is significantly less expensive than the originator but, because of 
difference in appearance, is not adhered to by a proportion of patients.  These patients may 
experience a recurrence of symptoms, impairment of quality of life etc, depending on the disease 
being managed.  If worsening of symptoms were to lead to hospital attendance, additional test etc, 
then the savings would soon evaporate, and costs could increase overall [20].  While this may be 
somewhat theoretical, with little direct evidence, it is nonetheless plausible, especially as the cost of 
hospitalisation and associated care considerably exceeds the likely savings, even if this is a rare 
occurrence [76]. 
Conclusion 
As we have demonstrated in this paper a lack of consideration of the acceptability of the generic 
product could undermine treatment efficacy and safety in certain populations, and thereby reduce 
the potential considerable cost saving that could be achieved by promoting the use of generic 
medicines.  Failure to produce a generic that is acceptable to the patient and their caregiver can not 
only lead to potential for treatment failure via non concordance with therapy but potentially also 
significant extra costs.  Thus, ensuring substantial cost savings by promoting use of generic products 
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requires equality in term of not only quality, safety and efficacy in clinical studies, but also acceptability 
and hence efficacy in use. 
Given the current International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) focus on unifying guidance on the development and scrutiny of 
generics [77] it is very timely to state our position on this topic [78] and to seek to influence the 
growing debate to ensure that acceptability is included alongside the other factors being considered 
for harmonization. 
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september-2018-for-website.pdf. January 23, 2020 
73 Apotheke adhoc. [Glaucoma: Injection of virus instead of eye drops?]. https://www.apotheke-
adhoc.de/nachrichten/detail/pharmazie/glaukom-virus-injektion-statt-
augentropfenaugenerkrankungen//print.html. May 20, 2020 
74 Scottish Medicines Consortium. Mercaptopurine 20mg/mL oral suspension (Xaluprine®). SMC 
No: 798/12. 
https://www.scottishmedicines.org.uk/media/1977/mercaptopurine_oral_suspension_xalup
rine_abbreviated_final_july_2012_for_website.pdf. January 23, 2020 
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eviated_final_june_2017_for_website.pdf. January 23, 2020 
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Reference number Article Category Medication Population Method Key findings
39
Bagger-Sjoback D., et al. 1989. Taste evaluation and 
compliance of two paediatric formulations of 
phenoxymethylpenicillin in children. Scand J Prim Health 
Care. 7:87-92.
Drugs Evaluation 2 penicillin suspensions Children 3–10 years with otitis media
Child’s spontaneous verbal judgment and parent’s judgment of 
acceptability.
No differences in taste scores between two suspensions.
33
Baguley D., et al. 2012. Prescribing for children - taste and 
palatability affect adherence to antibiotics: a review. Arch 
Dis Child. 97(3): 293-7.
Review Antibiotics Paediatric
Reviewing the clinical evidence around palatability of 
antibiotics.
Certain drugs, for example flucloxacillin, are so unpalatable that they should 
not be prescribed as syrups without prior ‘taste testing’ in an individual child, 
while others, such as oral cephalosporins, are accepted very well although 
they are more expensive with a broader antimicrobial spectrum than may 
be strictly necessary.
21
Belissa E., et al. 2019. Acceptability of oral liquid 
pharmaceutical products in older adults: palatability and 
swallowability issues. BMC Geriatrics. 19(1), 1-9.
Drugs Evaluation Oral liquid pharmaceutical products Elderly
Explorations were performed using the CAST - ClinSearch 
Acceptability Score Test®.
Oral liquid pharmaceutical products are a suboptimal alternative to solid 
oral dosage forms in patients with swallowing disorders. Palatability 
remains crucial in older populations, especially for women.
29
Cohen R., et al. 2009. Study of the acceptability of antibiotic 
syrups, suspensions, and oral solutions prescribed to 
pediatric outpatients.  Eur J Pediatr. 168(7):851-7.
Drugs Evaluation
3 antibiotic syrups, suspensions, and oral solutions most often 
prescribed to children in France: amoxicillin–clavulanic acid 
(princeps and generics), amoxicillin (princeps and generics) and 
cefpodoxime proxetil (princeps as no generics were available)
953 children from 0.5 months to 14 years to whom a 
pediatrician had prescribed an antibiotic in the form of a syrup, 
suspension, or oral solution
Taste assessment based on representations of five facial 
expressions.
Differences in palatability and acceptability between amoxicillin–clavulanic 
acid reference products and some generics. Such differences do not appear 
between amoxicillin reference products and amoxicillin generics.
not discussed [only abstract, 
full article not found]
Demers D.M., et al. 1994. Antimicrobial drug suspensions: a 
blinded comparison of taste of twelve common pediatric 
drugs including cefixime, cefpodoxime, cefprozil and 
loracarbef.  Pediatr Infect Dis J. 13(2):87-9.
Drugs Evaluation
12 antimicrobial suspensions including Lorabid, Keflex, Suprax, 
Cefzil, Augmentin, Vantin, Ceclor, Sulfatrim, Pediazole, 
Dynapen, V-Cillin-K, Veetids and two penicillin VK suspensions
Paediatric Smell, texture, taste, aftertaste and overall acceptance.
No difference overall was detected between the two penicillin VK 
suspensions evaluated.
47
Desai R.J., et al. 2018. Differences in rates of switchbacks 
after switching from branded to authorized generic and 
branded to generic drug products: cohort study. BMJ. 
3;361:k1180.
Cohort Study
Branded products and  authorized generics (same active 
ingredients, appearance, and excipients as the branded 
product) or generic drug products (same active ingredients as 
the branded product but may differ in appearance and 
excipients) for one of the study drugs: alendronate tablets, 
amlodipine tablets, amlodipine-benazepril capsules, calcitonin 
salmon nasal spray, escitalopram tablets, glipizide extended 
release tablets, quinapril tablets, and sertraline tablets.
94 909 patients switched from branded to authorized generic 
drug products and 116 017 patients switched from branded to 
generic drug products
Switchbacks to the branded drug product in the year after their 
switch to an authorized generic or a generic drug product.
Switching from branded to authorized generic drug products was associated 
with lower switchback rates compared with switching from branded to 
generic drug products.
10
El-Chaar G.M., et al. 1996. Randomized, double blind 
comparison of brand and generic antibiotic suspensions: II. A 
study of taste and compliance in children. Pediatr Infect Dis 
J. 15:18-22.
Drugs Evaluation
Brand and generic antibiotic suspensions of cephalexin, 
erythromycinsulfisoxazole and trimethoprimsulfamethoxazole 
approved in the US
Children 3–14 years with clinical indication
Patient’s verbal response and facial hedonic scale to rate taste 
and aftertaste, and parent’s rating of ease of administering 
medication.
For cephalexin, and for erythromycin-sulfisoxazole: no significant 
differences between generic products and the innovator in terms of taste 
and compliance. For trimethoprim-sulfamethoxazole, the innovator tasted 
better than the generic product, but there was no difference in compliance.
not discussed [no focus on 
drugs]
Figueiras M.J., et al. 2009. Assessing lay beliefs about generic 
medicines: Development of the generic medicines scale. 
Psychol Health Med. 14(3):311-21.
Tool development Generic medicines
228 Portuguese pilot study (Stage I)
819 Portuguese main study (Stage II)
Development of the generic medicines scale (GMS)
Stage I: item generation and pilot study
Stage II: main study
Two-factor structure concerning beliefs about generic medicines, 
comprising two core themes: efficacy and similarity to brand medicines.
31
Gauzit R., et al. 2012. Generic antibiotic drugs: is 
effectiveness guaranteed? Médecine et maladies 
infectieuses. 42(4):141-148.
Review Generic antibiotic drugs - -
There is a specific problem of taste and treatment acceptability for pediatric 
oral antibiotic drugs. It seems necessary to review regulations for marketing 
authorization of generic antibiotic drugs.
36
Inoue Y., et al. 2012. Study of the physicochemical 
properties of tulobuterol dry syrups using taste and smell 
sensors. Chem Pharm Bull (Tokyo). 60(4):442-8.
Drugs Evaluation Tulobuterol Dry Syrup in its original form and 2 generic forms
25 healthy well-trained human volunteers with an average age 
of 23 years
Gustatory sensation tests, taste and smell sensors, and 
physicochemical properties measurement.
Differences in preparations were presumably caused by variations in 
manufacturing specifications, such as types of additives and their content 
and coating methods used.
not discussed [Informal taste 
test]
Ito M.K., et al. 1999. A matter of taste. Am J Health Syst 
Pharm. 56(1):80-1.
Drugs Evaluation
2 bile acid sequestrants mixtures: Prevalite (generic) and 
Questran Light (innovator)
10 tasters from pharmacy administrative personnel at health 
system
Informal taste test: 5-point scale for taste, texture and smell.
Tasters preferred Questran Light over Prevalite for taste, smell and overall 
quality.
27
Jahnsen T., et al. 1987. An acceptability study of two 
pivampicillin mixtures in children in general practice. Scand J 
Prim Health Care. 5:241-243.
Drugs Evaluation 2 pivampicillin mixtures Children 1–7 years with infection
Child’s evaluation of taste or parent’s evaluation of 
administration.
Better acceptability and easier administration with banana than cocoa-
peppermint taste.
not discussed [only abstract, 
full article in Polish]
Kardas P., et al. 2005. [A blinded comparison of palatability 
of 13 common pediatric antibiotic suspensions].  Wiad Lek. 
58(1-2):15-20.
Drugs Evaluation 13 antibiotic suspensions 25 volunteers
Appearance, smell, texture, taste and aftertaste compared to 
amoxycillin (Amotaks) as a reference drug.
In overall score, different preparations of the same substance obtained 
similar scores, statistically non-different, with one exception for 
clarithromycin, in which Klacid was characterized by better palatability.
34
Kim M.K., et al. 2006. Vomiting of liquid corticosteroids in 
children with asthma. Pediatr Emerg Care. 22:397-401.
Drugs Evaluation 2 prednisolone liquid preparations Children 2–10 years with acute asthma exacerbation Five point facial hedonic scale (>5 years of age). Better taste score for Orapred than generic prednisolone.
not discussed [ocular 
formulations in adults]
Kim Y.I., et al. 2015. Efficacy and Safety of Glaucoma 
Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-
Combination Brand-Name Drug to Its Generic Counterpart.  
J Ocul Pharmacol Ther.31(6):335-9.
Drugs Evaluation
2 eye drops: brand-name and generic of 2% dorzolamide/0.5% 
timolol fixed-combination drugs (DTFC)
112 patients with a mean age of ≈ 63 years
Questionnaire on discomfort symptoms and on discomfort 
score for the use of eye drops.
There were higher incidences of bitter taste and blurring with Cosopt (brand-
name), and there was a higher incidence of headache with Batidor (generic), 
but no significant differences (P > 0.05) were noted. There was, likewise, no 
significant difference in the discomfort score between 2 drugs.
40
Kraus M., et al. 2001. Effectiveness and Infant Acceptance 
of the Rx Medibottle versus the Oral Syringe. 
Pharmacotherapy. 21(4):416–423.
Device Evaluation
Acetaminophen (Tempra syrup) delivered by the Rx medibottle 
or with an oral syringe
30 healthy, bottle‐fed infants, aged 2–14 months, receiving 
routine vaccinations
Effectiveness was based on the percentage of infants receiving 
100% of the intended dose. Infant acceptance was scored 
using a validated infant medication acceptance scale (MAS).
Significantly more infants received 100% of the intended dose with the Rx 
medibottle (93.3%) than with the oral syringe (56.7%, p=0.0074). Infants had 
a significantly higher mean MAS score when using the Rx medibottle (8.3 ± 
1.8 vs 7.3 ± 1.7, p=0.002). A significantly higher percentage had ideal MAS 
scores of 9 or above with the Rx medibottle (73%) compared with the oral 
syringe (17%, p=0.0001).
not discussed [only abstract, 
full article in Japanese]
Matsuo R., et al. 2008. [Bitterness of the mixture of 
clarithromycin dry syrup and carbocisteine preparation--
difference between brand name and generic drugs]. 
Yakugaku Zasshi. 128(3):479-85.
Drugs Evaluation
Mixture of clarithromycin dry syrup and carbocisteine 
preparation: brand name and generic
6 healthy male volunteers Human gustatory sensation tests.
The extent of bitterness of the mixture of clarithromycin dry syrup and 
carbocisteine preparation highly varies among the generic formulations.
not discussed [only abstract, 
full article in Japanese]
Miura Y., et al. 2007. [Sensory evaluation test: odor 
component analysis and endotoxin content of Krestin and 
Carbocrin (generic drug) to compare palatability].  Gan To 
Kagaku Ryoho. 34(8):1259-63.
Drugs Evaluation Krestin and Carbocrin (generic drugs) No information
Sensory evaluation test. Questions were asked on the odor, 
taste, feeling on the tongue, and overall evaluation, to find out 
which is easier to swallow.
Krestin is significantly superior to Carbocrin, showing a clear difference in 
palatability between the two products.
46
Riner B., et al. 2017. "No generics, Doctor!" The perspective 
of general practitioners in two French regions. BMC Health 
Serv Res. 17(1):707.
Survey Generic medicines 316 General practitioners from Marinique & Guadeloupe Survey
The main reported disadvantage concerned "Patients may be confused by 
changes in presentation" (47% of the questioned practitioners), then 
"Presentation and dosage form differ between laboratories for the same 
molecule" (44% of the questioned practitioners). They were caught between 
the requirements of health insurance regimes and the opposition of 
numerous users and suggested that the patient information provided by 
health authorities should be improved and that drug composition and 
packaging should be made uniform. One of the simplest solutions to make 
generics more acceptable to both prescribers and patients could be 
uniformization of their presentations by delivering exact copies (same active 
and inactive ingredients) or the same generic product to the same patient 
for a given originator product.
6
Ruiz F., et al. 2019. Sex Differences in Medicine 
Acceptability: A New Factor to Be Considered in Medicine 
Formulation. Pharmaceutics. 11(8):368
Drugs Evaluation 2 original formulations of memantine: tablets and oral solution Elderly
Evaluations were scored with the acceptability reference 
framework (CAST - ClinSearch Acceptability Score Test®) and 
the rodent Brief Access Taste Aversion (BATA) model tested 
aversiveness.
Acceptability issues with the original oral solution of memantine driven by 
palatability. According to CAST the coated tablet, which created a physical 
barrier between the memantine hydrochloride and taste buds, was well 
accepted in the older population, while this appeared not to be the case for 
the oral solution. The BATA model objectively confirmed the aversiveness of 
this formulation. Exploring sex differences, consistent findings from both 
human studies and animal models highlighted a higher sensitivity of the 
females to this unpalatable oral formulation as the proposed cause for 
suboptimal acceptability.
9
Samulak K.M., et al. 1996. Randomized, double blind 
comparison of brand and generic antibiotic suspensions: I. A 
study of taste in adults. Pediatr Infect Dis J. 15(1):14-17.
Drugs Evaluation
Generic products of cephalexin, erythromycin 
ethylsuccinatesulfisoxazole, penicillin V, and 
trimethoprimsulfamethoxazole approved in the US
42 adult volunteers
Subjects tasted one class of brand and generic antibiotics and 
rated them according to smell, texture, taste and aftertaste.
At least one generic preparation of cephalexin, erythromycin 
ethylsuccinate/sulfisoxazole and penicillin V potassium was rated equal in 
taste to the respective brand name products. However, brand erythromycin 
estolate and trimethoprim-sulfamethoxazole name brand suspensions rated 
significantly higher than the other products tested. For cephalexin, penicillin 
V and erythromycin ethylsuccinate/sulfisoxazole: the taste of generic 
products was rated equal to that of the innovators. For trimethoprim-
sulfamethoxazole and erythromycin estolate, the taste of the innovators 
was rated higher than that of the generic products
25
Sjövall J., et al. 1984. Methods for evaluating the taste of 
paediatric formulations in children: A comparison between 
the facial hedonic method and the patients' own 
spontaneous verbal judgement. European journal of 
pediatrics. 141(4):243-247.
Drugs Evaluation
3 oral suspensions of bacampicillin. 2 penicillin syrups were 
included as reference drugs, formulation W assumed to be 
pleasant to the taste and formulation U assumed to have an 
unacceptable taste on the basis of clinical experience.
103 children with upper respiratory tract infections - 3-12 
years of age - with signs of bacterial infection for which 
treatment with penicillin was indicated
Patient's own spontaneous verbal judgement and hedonic 
scale of facial expressions.
Formulation W must be considered the most liked one, while the U and C 
formulations were liked the least. The A and B formulations were ranked in 
between.
28
Stevens R, et al. 1996. A randomized study of ondansetron 
syrup in children: evaluation of taste acceptability and 
tolerance. Pediatr Hematol Oncol. 13:199-202.
Drugs Evaluation 2 flavours of ondansetron syrup Children 3–12 years undergoing chemotherapy Panel of five faces and asked preference. Preference for strawberry formulation
32
Tattevin P., et al. 2013. Efficacy and quality of antibacterial 
generic products approved for human use: a systematic 
review. Clinical infectious diseases. 58(4):458-469.
Review Generic medicines -
Search on Medline and Embase for original research articles on 
antibacterial generic products published in English or French 
before July 2013.
Of the 37 studies, 14 (37.8%) suggested that some generic products may be 
inferior to the innovator in terms of purity (n=2), in vitro activity (n=3), in 
vivo efficacy in experimental models (n=4), clinical efficacy (n=2), taste 
(n=2), or compliance and acceptability in children (n=1).
37
Tokuyama E., et al. 2009. Famotidine Orally Disintegrating 
Tablets: Bitterness Comparison of Original and Generic 
Products. Chemical and Pharmaceutical Bulletin. 57(4):382-
387.
Drugs Evaluation
9 formulations of famotidine orally disintegrating tablets: the 
original manufacturer’s formulation and eight generic versions
11 well-trained volunteers
Human gustatory sensation tests, a comparison of the release 
profiles, and taste sensor measurements.
The bitterness intensities of the generic products A, E and F showed 
significantly stronger bitterness compared with the original product, while 
no significant differences in sweetness scores were found between the 
original and the generic products, which was significantly less sweet than 
the original product. Among the eight generic products tested, the variance 
in the sweetness intensity was not great, but there were large variances in 
the intensity of bitterness, some of the generic products being significantly 
more bitter than that of the original product. On the other hand, some 
generic products show similar bitterness level as the original product.
45
Toverud E.L., et al. 2011. Norwegian patients on generic 
antihypertensive drugs: a qualitative study of their own 
experiences. Eur J Clin Pharmacol. 67(1):33-8.
Survey Generic antihypertensive drugs
22 patients from pharmacies in Oslo who had taken brand 
antihypertensive products as well as substituted generic 
products
Focus-group discussions.
Most reported low drug adherence before and after generic substitution. 
Differences in name, color, form, or taste caused confusion.
41
U.S. Department of Health and Human Services. Food and 
Drug Administration. 2015. Size, shape, and other physical 
attributes of generic tablets and capsules guidance for 
industry. Fed. Regist.:35366–35367
Guidance Generic tablets and capsules - -
Differences in physical characteristics (e.g., size and shape of the tablet or 
capsule) may affect patient compliance and acceptability of medication 
regimens or could lead to medication errors. 
38
Uchida T., et al. 2013. Evaluation of palatability of 10 
commercial amlodipine orally disintegrating tablets by 
gustatory sensation testing, OD-mate as a new 
disintegration apparatus and the artificial taste sensor. 
Journal of Pharmacy and Pharmacology. 65(9):1312-1320.
Drugs Evaluation
10 formulations of amlodipine orally disintegrating tablets: the 
original manufacturer’s formulation and nine generic versions
6 healthy female subjects, 26  +/- 9 years old
Human gustatory sensation testing (bitterness intensity, 
disintegration time in the mouth, palatability in the mouth and 
after splitting out), disintegration/dissolution testing, and the 
evaluation of bitterness intensity using a taste sensor.
The factors most affecting the palatability of amlodipine ODTs were found 
to be disintegration and taste.
not discussed [proxy 
measure]
Uestuener P., et al. 2014. Taste acceptability of pulverized 
brand-name and generic drugs containing amlodipine or 
candesartan.  Int J Pharm. 468(1-2):196-8.
Drugs Evaluation
the brand-name and the most prescribed generic medicines 
containing either amlodipine, a popular calcium-channel 
blocker with a bitter taste, or candesartan, a recognized 
angiotensin type 2 receptor antagonist
healthy health care workers: 19 nurses and 12 physicians aged 
between 25 and 49 years.
A smiley-face scale depicting four degrees of pleasure.
Pulverized brand-names and generics containing either amlodipine or 
candesartan did not differ with respect to their taste acceptability.
26
Uhari M., et al. 1986. Acceptance of Antibiotic Mixtures by 
Infants and Children. Eur J Clin Pharmacol. 30:503-504.
Drugs Evaluation
containing either amlodipine, a popular calcium-channel 
blocker
76 patients range 0.2 to 8.1 years
The time a nurse required to give the drug to a child was 
recorded and a score of the acceptance was given by the 
nurse.
The time difference was significantbetween erythromycin Brand 1 and 2, 
while the difference between the two penicillin products was not 
significant.
35
Woertz K., et al. 2011. Development of a taste-masked 
generic ibuprofen suspension: top-down approach guided by 
electronic tongue measurements. J Pharm Sci. 100(10):4460-
70.
Drugs Evaluation
with a bitter taste, or candesartan, a recognized angiotensin 
type 2
- Electronic Tongue Measurements.
The results from the electronic tongue measurements clearly showed that 
the formulations could be distinguished according to their excipients and 
manufacturer.
30
Wollner A., et al. 2011. Acceptability, compliance and 
schedule of administration of oral antibiotics in outpatient 
children. Archives de pediatrie: organe officiel de la Societe 
francaise de pediatrie. 18(5):611-616.
Drugs Evaluation receptor antagonist 1482 patients < 6 years
Taste assessment based on representations of five facial 
expressions.
This study confirms the disparity in terms of acceptability among the 
different antibiotics prescribed for children even for the same drug, 
warranting evaluation for marketing of future generic drugs pediatric oral 
suspension.
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39
Bagger-Sjoback D., et al. 1989. Taste evaluation and 
compliance of two paediatric formulations of 
phenoxymethylpenicillin in children. Scand J Prim Health 
Care. 7:87-92.
Drugs Evaluation 2 penicillin suspensions Children 3–10 years with otitis media
Child’s spontaneous verbal judgment and parent’s judgment of 
acceptability.
No differences in taste scores between two suspensions.
33
Baguley D., et al. 2012. Prescribing for children - taste and 
palatability affect adherence to antibiotics: a review. Arch 
Dis Child. 97(3): 293-7.
Review Antibiotics Paediatric
Reviewing the clinical evidence around palatability of 
antibiotics.
Certain drugs, for example flucloxacillin, are so unpalatable that they should 
not be prescribed as syrups without prior ‘taste testing’ in an individual child, 
while others, such as oral cephalosporins, are accepted very well although 
they are more expensive with a broader antimicrobial spectrum than may 
be strictly necessary.
21
Belissa E., et al. 2019. Acceptability of oral liquid 
pharmaceutical products in older adults: palatability and 
swallowability issues. BMC Geriatrics. 19(1), 1-9.
Drugs Evaluation Oral liquid pharmaceutical products Elderly
Explorations were performed using the CAST - ClinSearch 
Acceptability Score Test®.
Oral liquid pharmaceutical products are a suboptimal alternative to solid 
oral dosage forms in patients with swallowing disorders. Palatability 
remains crucial in older populations, especially for women.
29
Cohen R., et al. 2009. Study of the acceptability of antibiotic 
syrups, suspensions, and oral solutions prescribed to 
pediatric outpatients.  Eur J Pediatr. 168(7):851-7.
Drugs Evaluation
3 antibiotic syrups, suspensions, and oral solutions most often 
prescribed to children in France: amoxicillin–clavulanic acid 
(princeps and generics), amoxicillin (princeps and generics) and 
cefpodoxime proxetil (princeps as no generics were available)
953 children from 0.5 months to 14 years to whom a 
pediatrician had prescribed an antibiotic in the form of a syrup, 
suspension, or oral solution
Taste assessment based on representations of five facial 
expressions.
Differences in palatability and acceptability between amoxicillin–clavulanic 
acid reference products and some generics. Such differences do not appear 
between amoxicillin reference products and amoxicillin generics.
not discussed [only abstract, 
full article not found]
Demers D.M., et al. 1994. Antimicrobial drug suspensions: a 
blinded comparison of taste of twelve common pediatric 
drugs including cefixime, cefpodoxime, cefprozil and 
loracarbef.  Pediatr Infect Dis J. 13(2):87-9.
Drugs Evaluation
12 antimicrobial suspensions including Lorabid, Keflex, Suprax, 
Cefzil, Augmentin, Vantin, Ceclor, Sulfatrim, Pediazole, 
Dynapen, V-Cillin-K, Veetids and two penicillin VK suspensions
Paediatric Smell, texture, taste, aftertaste and overall acceptance.
No difference overall was detected between the two penicillin VK 
suspensions evaluated.
47
Desai R.J., et al. 2018. Differences in rates of switchbacks 
after switching from branded to authorized generic and 
branded to generic drug products: cohort study. BMJ. 
3;361:k1180.
Cohort Study
Branded products and  authorized generics (same active 
ingredients, appearance, and excipients as the branded 
product) or generic drug products (same active ingredients as 
the branded product but may differ in appearance and 
excipients) for one of the study drugs: alendronate tablets, 
amlodipine tablets, amlodipine-benazepril capsules, calcitonin 
salmon nasal spray, escitalopram tablets, glipizide extended 
release tablets, quinapril tablets, and sertraline tablets.
94 909 patients switched from branded to authorized generic 
drug products and 116 017 patients switched from branded to 
generic drug products
Switchbacks to the branded drug product in the year after their 
switch to an authorized generic or a generic drug product.
Switching from branded to authorized generic drug products was associated 
with lower switchback rates compared with switching from branded to 
generic drug products.
10
El-Chaar G.M., et al. 1996. Randomized, double blind 
comparison of brand and generic antibiotic suspensions: II. A 
study of taste and compliance in children. Pediatr Infect Dis 
J. 15:18-22.
Drugs Evaluation
Brand and generic antibiotic suspensions of cephalexin, 
erythromycinsulfisoxazole and trimethoprimsulfamethoxazole 
approved in the US
Children 3–14 years with clinical indication
Patient’s verbal response and facial hedonic scale to rate taste 
and aftertaste, and parent’s rating of ease of administering 
medication.
For cephalexin, and for erythromycin-sulfisoxazole: no significant 
differences between generic products and the innovator in terms of taste 
and compliance. For trimethoprim-sulfamethoxazole, the innovator tasted 
better than the generic product, but there was no difference in compliance.
not discussed [no focus on 
drugs]
Figueiras M.J., et al. 2009. Assessing lay beliefs about generic 
medicines: Development of the generic medicines scale. 
Psychol Health Med. 14(3):311-21.
Tool development Generic medicines
228 Portuguese pilot study (Stage I)
819 Portuguese main study (Stage II)
Development of the generic medicines scale (GMS)
Stage I: item generation and pilot study
Stage II: main study
Two-factor structure concerning beliefs about generic medicines, 
comprising two core themes: efficacy and similarity to brand medicines.
31
Gauzit R., et al. 2012. Generic antibiotic drugs: is 
effectiveness guaranteed? Médecine et maladies 
infectieuses. 42(4):141-148.
Review Generic antibiotic drugs - -
There is a specific problem of taste and treatment acceptability for pediatric 
oral antibiotic drugs. It seems necessary to review regulations for marketing 
authorization of generic antibiotic drugs.
36
Inoue Y., et al. 2012. Study of the physicochemical 
properties of tulobuterol dry syrups using taste and smell 
sensors. Chem Pharm Bull (Tokyo). 60(4):442-8.
Drugs Evaluation Tulobuterol Dry Syrup in its original form and 2 generic forms
25 healthy well-trained human volunteers with an average age 
of 23 years
Gustatory sensation tests, taste and smell sensors, and 
physicochemical properties measurement.
Differences in preparations were presumably caused by variations in 
manufacturing specifications, such as types of additives and their content 
and coating methods used.
not discussed [Informal taste 
test]
Ito M.K., et al. 1999. A matter of taste. Am J Health Syst 
Pharm. 56(1):80-1.
Drugs Evaluation
2 bile acid sequestrants mixtures: Prevalite (generic) and 
Questran Light (innovator)
10 tasters from pharmacy administrative personnel at health 
system
Informal taste test: 5-point scale for taste, texture and smell.
Tasters preferred Questran Light over Prevalite for taste, smell and overall 
quality.
27
Jahnsen T., et al. 1987. An acceptability study of two 
pivampicillin mixtures in children in general practice. Scand J 
Prim Health Care. 5:241-243.
Drugs Evaluation 2 pivampicillin mixtures Children 1–7 years with infection
Child’s evaluation of taste or parent’s evaluation of 
administration.
Better acceptability and easier administration with banana than cocoa-
peppermint taste.
not discussed [only abstract, 
full article in Polish]
Kardas P., et al. 2005. [A blinded comparison of palatability 
of 13 common pediatric antibiotic suspensions].  Wiad Lek. 
58(1-2):15-20.
Drugs Evaluation 13 antibiotic suspensions 25 volunteers
Appearance, smell, texture, taste and aftertaste compared to 
amoxycillin (Amotaks) as a reference drug.
In overall score, different preparations of the same substance obtained 
similar scores, statistically non-different, with one exception for 
clarithromycin, in which Klacid was characterized by better palatability.
34
Kim M.K., et al. 2006. Vomiting of liquid corticosteroids in 
children with asthma. Pediatr Emerg Care. 22:397-401.
Drugs Evaluation 2 prednisolone liquid preparations Children 2–10 years with acute asthma exacerbation Five point facial hedonic scale (>5 years of age). Better taste score for Orapred than generic prednisolone.
not discussed [ocular 
formulations in adults]
Kim Y.I., et al. 2015. Efficacy and Safety of Glaucoma 
Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-
Combination Brand-Name Drug to Its Generic Counterpart.  
J Ocul Pharmacol Ther.31(6):335-9.
Drugs Evaluation
2 eye drops: brand-name and generic of 2% dorzolamide/0.5% 
timolol fixed-combination drugs (DTFC)
112 patients with a mean age of ≈ 63 years
Questionnaire on discomfort symptoms and on discomfort 
score for the use of eye drops.
There were higher incidences of bitter taste and blurring with Cosopt (brand-
name), and there was a higher incidence of headache with Batidor (generic), 
but no significant differences (P > 0.05) were noted. There was, likewise, no 
significant difference in the discomfort score between 2 drugs.
40
Kraus M., et al. 2001. Effectiveness and Infant Acceptance 
of the Rx Medibottle versus the Oral Syringe. 
Pharmacotherapy. 21(4):416–423.
Device Evaluation
Acetaminophen (Tempra syrup) delivered by the Rx medibottle 
or with an oral syringe
30 healthy, bottle‐fed infants, aged 2–14 months, receiving 
routine vaccinations
Effectiveness was based on the percentage of infants receiving 
100% of the intended dose. Infant acceptance was scored 
using a validated infant medication acceptance scale (MAS).
Significantly more infants received 100% of the intended dose with the Rx 
medibottle (93.3%) than with the oral syringe (56.7%, p=0.0074). Infants had 
a significantly higher mean MAS score when using the Rx medibottle (8.3 ± 
1.8 vs 7.3 ± 1.7, p=0.002). A significantly higher percentage had ideal MAS 
scores of 9 or above with the Rx medibottle (73%) compared with the oral 
syringe (17%, p=0.0001).
not discussed [only abstract, 
full article in Japanese]
Matsuo R., et al. 2008. [Bitterness of the mixture of 
clarithromycin dry syrup and carbocisteine preparation--
difference between brand name and generic drugs]. 
Yakugaku Zasshi. 128(3):479-85.
Drugs Evaluation
Mixture of clarithromycin dry syrup and carbocisteine 
preparation: brand name and generic
6 healthy male volunteers Human gustatory sensation tests.
The extent of bitterness of the mixture of clarithromycin dry syrup and 
carbocisteine preparation highly varies among the generic formulations.
not discussed [only abstract, 
full article in Japanese]
Miura Y., et al. 2007. [Sensory evaluation test: odor 
component analysis and endotoxin content of Krestin and 
Carbocrin (generic drug) to compare palatability].  Gan To 
Kagaku Ryoho. 34(8):1259-63.
Drugs Evaluation Krestin and Carbocrin (generic drugs) No information
Sensory evaluation test. Questions were asked on the odor, 
taste, feeling on the tongue, and overall evaluation, to find out 
which is easier to swallow.
Krestin is significantly superior to Carbocrin, showing a clear difference in 
palatability between the two products.
46
Riner B., et al. 2017. "No generics, Doctor!" The perspective 
of general practitioners in two French regions. BMC Health 
Serv Res. 17(1):707.
Survey Generic medicines 316 General practitioners from Marinique & Guadeloupe Survey
The main reported disadvantage concerned "Patients may be confused by 
changes in presentation" (47% of the questioned practitioners), then 
"Presentation and dosage form differ between laboratories for the same 
molecule" (44% of the questioned practitioners). They were caught between 
the requirements of health insurance regimes and the opposition of 
numerous users and suggested that the patient information provided by 
health authorities should be improved and that drug composition and 
packaging should be made uniform. One of the simplest solutions to make 
generics more acceptable to both prescribers and patients could be 
uniformization of their presentations by delivering exact copies (same active 
and inactive ingredients) or the same generic product to the same patient 
for a given originator product.
6
Ruiz F., et al. 2019. Sex Differences in Medicine 
Acceptability: A New Factor to Be Considered in Medicine 
Formulation. Pharmaceutics. 11(8):368
Drugs Evaluation 2 original formulations of memantine: tablets and oral solution Elderly
Evaluations were scored with the acceptability reference 
framework (CAST - ClinSearch Acceptability Score Test®) and 
the rodent Brief Access Taste Aversion (BATA) model tested 
aversiveness.
Acceptability issues with the original oral solution of memantine driven by 
palatability. According to CAST the coated tablet, which created a physical 
barrier between the memantine hydrochloride and taste buds, was well 
accepted in the older population, while this appeared not to be the case for 
the oral solution. The BATA model objectively confirmed the aversiveness of 
this formulation. Exploring sex differences, consistent findings from both 
human studies and animal models highlighted a higher sensitivity of the 
females to this unpalatable oral formulation as the proposed cause for 
suboptimal acceptability.
9
Samulak K.M., et al. 1996. Randomized, double blind 
comparison of brand and generic antibiotic suspensions: I. A 
study of taste in adults. Pediatr Infect Dis J. 15(1):14-17.
Drugs Evaluation
Generic products of cephalexin, erythromycin 
ethylsuccinatesulfisoxazole, penicillin V, and 
trimethoprimsulfamethoxazole approved in the US
42 adult volunteers
Subjects tasted one class of brand and generic antibiotics and 
rated them according to smell, texture, taste and aftertaste.
At least one generic preparation of cephalexin, erythromycin 
ethylsuccinate/sulfisoxazole and penicillin V potassium was rated equal in 
taste to the respective brand name products. However, brand erythromycin 
estolate and trimethoprim-sulfamethoxazole name brand suspensions rated 
significantly higher than the other products tested. For cephalexin, penicillin 
V and erythromycin ethylsuccinate/sulfisoxazole: the taste of generic 
products was rated equal to that of the innovators. For trimethoprim-
sulfamethoxazole and erythromycin estolate, the taste of the innovators 
was rated higher than that of the generic products
25
Sjövall J., et al. 1984. Methods for evaluating the taste of 
paediatric formulations in children: A comparison between 
the facial hedonic method and the patients' own 
spontaneous verbal judgement. European journal of 
pediatrics. 141(4):243-247.
Drugs Evaluation
3 oral suspensions of bacampicillin. 2 penicillin syrups were 
included as reference drugs, formulation W assumed to be 
pleasant to the taste and formulation U assumed to have an 
unacceptable taste on the basis of clinical experience.
103 children with upper respiratory tract infections - 3-12 
years of age - with signs of bacterial infection for which 
treatment with penicillin was indicated
Patient's own spontaneous verbal judgement and hedonic 
scale of facial expressions.
Formulation W must be considered the most liked one, while the U and C 
formulations were liked the least. The A and B formulations were ranked in 
between.
28
Stevens R, et al. 1996. A randomized study of ondansetron 
syrup in children: evaluation of taste acceptability and 
tolerance. Pediatr Hematol Oncol. 13:199-202.
Drugs Evaluation 2 flavours of ondansetron syrup Children 3–12 years undergoing chemotherapy Panel of five faces and asked preference. Preference for strawberry formulation
32
Tattevin P., et al. 2013. Efficacy and quality of antibacterial 
generic products approved for human use: a systematic 
review. Clinical infectious diseases. 58(4):458-469.
Review Generic medicines -
Search on Medline and Embase for original research articles on 
antibacterial generic products published in English or French 
before July 2013.
Of the 37 studies, 14 (37.8%) suggested that some generic products may be 
inferior to the innovator in terms of purity (n=2), in vitro activity (n=3), in 
vivo efficacy in experimental models (n=4), clinical efficacy (n=2), taste 
(n=2), or compliance and acceptability in children (n=1).
37
Tokuyama E., et al. 2009. Famotidine Orally Disintegrating 
Tablets: Bitterness Comparison of Original and Generic 
Products. Chemical and Pharmaceutical Bulletin. 57(4):382-
387.
Drugs Evaluation
9 formulations of famotidine orally disintegrating tablets: the 
original manufacturer’s formulation and eight generic versions
11 well-trained volunteers
Human gustatory sensation tests, a comparison of the release 
profiles, and taste sensor measurements.
The bitterness intensities of the generic products A, E and F showed 
significantly stronger bitterness compared with the original product, while 
no significant differences in sweetness scores were found between the 
original and the generic products, which was significantly less sweet than 
the original product. Among the eight generic products tested, the variance 
in the sweetness intensity was not great, but there were large variances in 
the intensity of bitterness, some of the generic products being significantly 
more bitter than that of the original product. On the other hand, some 
generic products show similar bitterness level as the original product.
45
Toverud E.L., et al. 2011. Norwegian patients on generic 
antihypertensive drugs: a qualitative study of their own 
experiences. Eur J Clin Pharmacol. 67(1):33-8.
Survey Generic antihypertensive drugs
22 patients from pharmacies in Oslo who had taken brand 
antihypertensive products as well as substituted generic 
products
Focus-group discussions.
Most reported low drug adherence before and after generic substitution. 
Differences in name, color, form, or taste caused confusion.
41
U.S. Department of Health and Human Services. Food and 
Drug Administration. 2015. Size, shape, and other physical 
attributes of generic tablets and capsules guidance for 
industry. Fed. Regist.:35366–35367
Guidance Generic tablets and capsules - -
Differences in physical characteristics (e.g., size and shape of the tablet or 
capsule) may affect patient compliance and acceptability of medication 
regimens or could lead to medication errors. 
38
Uchida T., et al. 2013. Evaluation of palatability of 10 
commercial amlodipine orally disintegrating tablets by 
gustatory sensation testing, OD-mate as a new 
disintegration apparatus and the artificial taste sensor. 
Journal of Pharmacy and Pharmacology. 65(9):1312-1320.
Drugs Evaluation
10 formulations of amlodipine orally disintegrating tablets: the 
original manufacturer’s formulation and nine generic versions
6 healthy female subjects, 26  +/- 9 years old
Human gustatory sensation testing (bitterness intensity, 
disintegration time in the mouth, palatability in the mouth and 
after splitting out), disintegration/dissolution testing, and the 
evaluation of bitterness intensity using a taste sensor.
The factors most affecting the palatability of amlodipine ODTs were found 
to be disintegration and taste.
not discussed [proxy 
measure]
Uestuener P., et al. 2014. Taste acceptability of pulverized 
brand-name and generic drugs containing amlodipine or 
candesartan.  Int J Pharm. 468(1-2):196-8.
Drugs Evaluation
the brand-name and the most prescribed generic medicines 
containing either amlodipine, a popular calcium-channel 
blocker with a bitter taste, or candesartan, a recognized 
angiotensin type 2 receptor antagonist
healthy health care workers: 19 nurses and 12 physicians aged 
between 25 and 49 years.
A smiley-face scale depicting four degrees of pleasure.
Pulverized brand-names and generics containing either amlodipine or 
candesartan did not differ with respect to their taste acceptability.
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Uhari M., et al. 1986. Acceptance of Antibiotic Mixtures by 
Infants and Children. Eur J Clin Pharmacol. 30:503-504.
Drugs Evaluation
containing either amlodipine, a popular calcium-channel 
blocker
76 patients range 0.2 to 8.1 years
The time a nurse required to give the drug to a child was 
recorded and a score of the acceptance was given by the 
nurse.
The time difference was significantbetween erythromycin Brand 1 and 2, 
while the difference between the two penicillin products was not 
significant.
35
Woertz K., et al. 2011. Development of a taste-masked 
generic ibuprofen suspension: top-down approach guided by 
electronic tongue measurements. J Pharm Sci. 100(10):4460-
70.
Drugs Evaluation
with a bitter taste, or candesartan, a recognized angiotensin 
type 2
- Electronic Tongue Measurements.
The results from the electronic tongue measurements clearly showed that 
the formulations could be distinguished according to their excipients and 
manufacturer.
30
Wollner A., et al. 2011. Acceptability, compliance and 
schedule of administration of oral antibiotics in outpatient 
children. Archives de pediatrie: organe officiel de la Societe 
francaise de pediatrie. 18(5):611-616.
Drugs Evaluation receptor antagonist 1482 patients < 6 years
Taste assessment based on representations of five facial 
expressions.
This study confirms the disparity in terms of acceptability among the 
different antibiotics prescribed for children even for the same drug, 
warranting evaluation for marketing of future generic drugs pediatric oral 
suspension.




Table 2 - Survey key findings 
Do some formal or informal discussions take place regarding acceptability  
of generic vs originator medicines? 
Yes Croatia If generic differs from reference in any characteristics, it would be explained 
and justified in a medicinal product dossier.  The dossier is then assessed by 
competent authorities during the marketing authorisation procedure. 
Netherlands For paediatric products, age-appropriateness of the formulation will be 




Denmark Generic application does not require evaluation of acceptability.  Only one 
application where palatability was tested in adults. 
Estonia Deviations from the originator will be discussed during the assessment of the 
marketing authorisation application. 
Greece Not much detail in the email. 
Ireland Considers appropriateness of various forms of medication for certain patient 
groups.  However, they do not have a formal standard operating procedure 
(SOP) for this. 
Latvia Issues will usually be discussed in EU member state delegate meetings. 
Slovakia Some discussion regarding acceptability took place around 10 years ago when 
generic prescription was legalized. 
Slovenia Not really answered in the email. The Agency for Medicinal Products and 
Medical Devices of the Republic of Slovenia (JAZMP) decides on the 
acceptability of Medicinal Products on the bases of positive risk/benefit ratio 
which is derived from the scientific Assessment Report prepared by the 
experts on the submitted documentation of given Medicinal Product.  This 
also applies for generic Medicinal Products.  In the European mutual 
recognition procedure (MRP) and decentralised procedure (DCP) marketing 
authorisations are granted on bases of Assessment Reports prepared by the 
Reference Member State (RMS). 
UK Assessment of paediatric medicines would take into account current regulatory 
guidance, most notably the EMA guideline “Pharmaceutical development of 
medicines for paediatric use” [12]. For adults, there is currently no 
requirement for generic versions of solid dosage forms to be the same size or 
shape as the originator. These aspects may nonetheless be considered during 
assessment where required. 
No Belgium  
Iceland  
Spain  
Sweden There is a formal review system after approval of generic product; they will 
evaluate the suitability of the product to be substituted at the pharmacy level 
with certain criteria. 
 
 
